Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has earned an average rating of “Moderate Buy” from the eight research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $48.50.

COLL has been the topic of several research reports. Piper Sandler reiterated a “neutral” rating and issued a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday, August 7th. Barclays decreased their price objective on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating for the company in a research note on Wednesday, August 19th. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings cut shares of Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, September 4th. Finally, Needham & Company LLC decreased their target price on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research report on Thursday, August 6th.

Collegium Pharmaceutical Stock Performance

Collegium Pharmaceutical stock traded down $0.07 during trading hours on Friday, hitting $22.31. 100,653 shares of the stock traded hands, compared to its average volume of 547,496. The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84. The firm’s 50 day moving average price is $29.41 and its 200-day moving average price is $32.82. The stock has a market capitalization of $726.41 million, a price-to-earnings ratio of 17.99 and a beta of 0.72. Collegium Pharmaceutical has a 1 year low of $21.65 and a 1 year high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The firm had revenue of $199.88 million during the quarter, compared to analysts’ expectations of $199.62 million. During the same period last year, the business posted $1.68 earnings per share. The company’s revenue for the quarter was up 6.3% compared to the same quarter last year. As a group, equities analysts expect that Collegium Pharmaceutical will post 6.19 EPS for the current fiscal year.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds have recently modified their holdings of COLL. WINTON GROUP Ltd purchased a new position in Collegium Pharmaceutical during the second quarter valued at approximately $536,000. Squarepoint Ops LLC lifted its holdings in Collegium Pharmaceutical by 124.8% in the second quarter. Squarepoint Ops LLC now owns 47,897 shares of the specialty pharmaceutical company’s stock valued at $1,734,000 after acquiring an additional 26,589 shares during the period. Corient Private Wealth LP boosted its position in Collegium Pharmaceutical by 60.5% in the 2nd quarter. Corient Private Wealth LP now owns 71,870 shares of the specialty pharmaceutical company’s stock worth $2,603,000 after purchasing an additional 27,097 shares in the last quarter. Amundi boosted its position in Collegium Pharmaceutical by 188.0% in the 2nd quarter. Amundi now owns 23,492 shares of the specialty pharmaceutical company’s stock worth $850,000 after purchasing an additional 15,336 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Collegium Pharmaceutical during the 2nd quarter worth approximately $295,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company’s portfolio includes treatments for pain and attention deficit hyperactivity disorder (ADHD), with an emphasis on products that address unmet patient and healthcare-provider needs.

Collegium’s pain portfolio includes Xtampza ER, an extended-release oxycodone product designed with abuse-deterrent properties; Nucynta and Nucynta ER, which contain tapentadol and are used to treat certain types of acute and chronic pain; and Belbuca, a buprenorphine buccal film for the management of chronic pain.